Kontron AG (KOTFY.PK) revealed a profit for third quarter that Dropped, from the same period last year
The company's bottom line totaled EUR17.88 million, or EUR0.0029 per share. This compares with EUR21.89 million, or EUR0.0035 per share, last year.
The company's revenue for the period fell 8.7% to EUR365.78 million from EUR400.76 million last year.
Kontron AG earnings at a glance (GAAP) :
-Earnings: EUR17.88 Mln. vs. EUR21.89 Mln. last year.-EPS: EUR0.0029 vs. EUR0.0035 last year.-Revenue: EUR365.78 Mln vs. EUR400.76 Mln last year.
For comments and feedback contact: [email protected]
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.